RCAP
ORIC icon

Resolute Capital Asset Partners’s Oric Pharmaceuticals ORIC Stock Holding History

Resolute Capital Asset Partners’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-167,515
Closed -$2.01M – 64
2025
Q3 		$2.01M Sell
167,515
-60,000
-26% -$631K 1.05% 30
2025
Q2 		$2.31M Buy
+227,515
New +$1.53M 1.21% 30

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Resolute Capital Asset Partners's ORIC Position: Q4 2025 in Review

Resolute Capital Asset Partners sold out of Oric Pharmaceuticals (ORIC) in Q4 2025, closing a stake of 167,515 shares — an estimated $2.01M sold.

Resolute Capital Asset Partners first reported a position in ORIC in Q2 2025 and held it in 2 quarters. The position peaked at $2.31M in Q2 2025. 164 funds tracked by Wall St. Rank hold ORIC as of Q4 2025.

  • Resolute Capital Asset Partners reported no remaining Oric Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Resolute Capital Asset Partners sold 167,515 Oric Pharmaceuticals shares in Q4 2025, an estimated $2.01M.
  • Resolute Capital Asset Partners first reported a position in Oric Pharmaceuticals in Q2 2025 and held it in 2 quarters.
  • Resolute Capital Asset Partners's Oric Pharmaceuticals position peaked at $2.31M in Q2 2025.
  • 164 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q4 2025.

Based on Resolute Capital Asset Partners's 13F filing for Q4 2025, filed 17 Feb 2026.